Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07127926 · ClinicalTrials.gov registry record
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
A clinical trial of Chronic Graft Versus Host Disease, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT07127926 is a study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07127926, a study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
Conditions Studied
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07127926
The ClinicalTrials.gov registry entry for NCT07127926 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (93% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07127926 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07127926 about?
NCT07127926 is a clinical study titled "Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD". The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
What is the current status of trial NCT07127926?
This trial is currently recruiting. The enrollment target is 8 participants. The study started on 2026-02-09. Estimated completion is 2027-12-31.
What conditions does trial NCT07127926 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.
Who is sponsoring clinical trial NCT07127926?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07127926 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
RECRUITING
-
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
-
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
RECRUITING · Phase 2
-
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.